Proteomic landscaping of high-grade serous ovarian carcinoma identifies stearoyl-CoA desaturase 5 as a potential predictive biomarker for poly(ADP-ribose) polymerase inhibitor response

Se Ik Kim; Hyeyoon Kim; Kisoon Dan; Hong-Beom Park; Cheol Lee; Hee Seung Kim; Hyun Hoon Chung; Jae-Weon Kim; Noh Hyun Park; Dohyun Han; Maria Lee

doi:10.1002/ctm2.1693

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (5) : e1693 DOI: 10.1002/ctm2.1693

LETTER TO THE JOURNAL

Proteomic landscaping of high-grade serous ovarian carcinoma identifies stearoyl-CoA desaturase 5 as a potential predictive biomarker for poly(ADP-ribose) polymerase inhibitor response

Se Ik Kim ¹^,²
, Hyeyoon Kim ³^,⁴
, Kisoon Dan ³
, Hong-Beom Park ⁵^,⁶
, Cheol Lee ⁷^,⁸
, Hee Seung Kim ¹^,²
, Hyun Hoon Chung ¹^,²
, Jae-Weon Kim ¹^,²
, Noh Hyun Park ¹^,²
, Dohyun Han ⁶^,⁹^,^†
, Maria Lee ¹^,²^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Se Ik Kim, Hyeyoon Kim, Kisoon Dan, Hong-Beom Park, Cheol Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Dohyun Han, Maria Lee. Proteomic landscaping of high-grade serous ovarian carcinoma identifies stearoyl-CoA desaturase 5 as a potential predictive biomarker for poly(ADP-ribose) polymerase inhibitor response. Clinical and Translational Medicine, 2024, 14(5): e1693 DOI:10.1002/ctm2.1693

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061.

[2]	Ledermann JA. PARP inhibitors in ovarian cancer. Ann Oncol. 2016;27(1):i40-i44.

[3]	Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512-2519.

[4]	Konstorum A, Lynch ML, Torti SV, Torti FM, Laubenbacher RC. A systems biology approach to understanding the pathophysiology of high-grade serous ovarian cancer: focus on iron and fatty acid metabolism. Omics. 2018;22(7):502-513.

[5]	Zhao G, Tan Y, Cardenas H, et al. Ovarian cancer cell fate regulation by the dynamics between saturated and unsaturated fatty acids. Proc Natl Acad Sci U S A. 2022;119(41):e2203480119.

[6]	Oatman N, Dasgupta N, Arora P, et al. Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Sci Adv. 2021;7(7).

[7]	Kim DS, Camacho CV, Kraus WL. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med. 2021;53(1):42-51.

[8]	Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18(12):773-791.

[9]	Miller RE, El-Shakankery KH, Lee J-Y. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies. J Gynecol Oncol. 2022;33(3).

[10]	Győrffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. Geroscience. 2023;45(3):1889-1898.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.